Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $44.0 million.

  • Voyager Therapeutics' Operating Expenses rose 1444.97% to $44.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.5 million, marking a year-over-year increase of 1087.07%. This contributed to the annual value of $163.3 million for FY2024, which is 2757.47% up from last year.
  • Voyager Therapeutics' Operating Expenses amounted to $44.0 million in Q3 2025, which was up 1444.97% from $41.8 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Operating Expenses registered a high of $44.6 million during Q2 2024, and its lowest value of $20.1 million during Q2 2022.
  • In the last 5 years, Voyager Therapeutics' Operating Expenses had a median value of $32.1 million in 2021 and averaged $32.7 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 3294.04% in 2022, then surged by 5642.46% in 2023.
  • Voyager Therapeutics' Operating Expenses (Quarter) stood at $22.4 million in 2021, then rose by 2.87% to $23.0 million in 2022, then surged by 56.42% to $36.0 million in 2023, then rose by 23.83% to $44.6 million in 2024, then dropped by 1.39% to $44.0 million in 2025.
  • Its Operating Expenses stands at $44.0 million for Q3 2025, versus $41.8 million for Q2 2025 and $41.2 million for Q1 2025.